EAM
Exome Asset Management Portfolio holdings
AUM
$202M
1-Year Est. Return
151.75%
This Fund
S&P 500
1 Year Est. Return
+151.75%
AUM
$151M
AUM Growth
+$41.1M
(+37%)
Holding
85
Top Buys
| 1 | +$9.28M | |
| 2 | +$4.89M | |
| 3 | +$3.6M | |
| 4 |
CVS Health
CVS
|
+$2.99M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$2.84M |
Top Sells
| 1 | +$2.99M | |
| 2 | +$2.5M | |
| 3 | +$2.49M | |
| 4 |
Verastem
VSTM
|
+$2.49M |
| 5 |
Geron
GERN
|
+$2.07M |
Sector Composition
| 1 | Healthcare | 97.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
VanEck Pharmaceutical ETF
PPH
$1.24B
| – | – |
0
|
|
||
77
Ultragenyx Pharmaceutical
RARE
$2.05B
| – | – |
0
|
|
||
78
Scholar Rock
SRRK
$4.62B
| – | – |
-84,339
|
|
||
79
Instil Bio
TIL
$60.2M
| – | – |
-16,200
|
|
||
80
UnitedHealth
UNH
$260B
| – | – |
0
|
|
||
|
81
Verastem
VSTM
$481M
| – | – |
-599,900
|
|
||
82
VYNE Therapeutics
VYNE
$19.8M
| – | – |
-208,970
|
|
||
|
ATYR
83
aTyr Pharma
ATYR
$80.7M
| – | – |
0
|
|